[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-sensitization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-sensitization":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,79,104,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641814","perioperative-quantitative-sensory-testing-and-incision-pain-mapping-in-thoracic-surgery-100641814",false,"NCT07653932","Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery","Perioperative Pain Phenotyping and Incision Pain Mapping Using Quantitative Sensory Testing in Patients Undergoing Thoracoscopic or Robotic-assisted Lung Resection: A Prospective Observational Pilot Cohort Study","Inclusion Criteria:\n\n1. Male\n2. Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.\n3. American Society of Anesthesiologists physical status I to III.\n4. Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.\n5. Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.\n\n3\\. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.\n\n4\\. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.\n\n5\\. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.\n\n6\\. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.\n\n7\\. Emergency surgery, conversion to open thoracotomy, extensive chest wall resection, or severe intraoperative complications.\n\n8\\. Any condition that, in the opinion of the investigator, makes the participant unsuitable for continued participation in the study.","MALE","18 Years",{"count":19,"type":20},46,"ESTIMATED","3 Months","OBSERVATIONAL","Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.\n\nThis prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.\n\nThe primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.\n\nThis study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.",[25,26,27,28,29,30],"Postoperative Pain","Chronic Postsurgical Pain","Thoracic Surgery","Lung Resection","Mechanical Hyperalgesia","Central Sensitization",[32,33,34,35,36],"Quantitative sensory testing","QST","Incision pain mapping","Thoracoscopic surgery","Perioperative pain phenotype","NOT_YET_RECRUITING","2026-06-13",{"date":40,"type":41},"2026-06-17","ACTUAL",{"date":43,"type":20},"2026-06-08",{"date":45,"type":20},"2027-02-28",{"name":47,"class":48},"Tongji Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100642999","investigation-of-pain-modulation-phenotypes-in-female-patients-with-fibromyalgia-100642999","NCT07640607","Investigation of Pain Modulation Phenotypes in Female Patients With Fibromyalgia","Inclusion Criteria:\n\n1. Having received a diagnosis of fibromyalgia according to the 2016 ACR diagnostic criteria\n2. Female patients aged 18-65\n3. Being literate\n4. Having signed the informed consent form upon agreeing to participate in the study\n\nExclusion Criteria:\n\n1. Being under 18 or over 65 years of age\n2. Having any condition that may lower the pain threshold or cause chronic pain (Rheumatoid Arthritis, Ankylosing Spondylitis, systemic inflammatory diseases, malignancies, etc.)\n3. Any neurological condition (stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, central nervous system malignancies…)\n4. Peripheral artery disease\n5. Severe cardiopulmonary insufficiency (stage 3-4)\n6. Uncontrolled systemic diseases such as hypertension and diabetes\n7. Presence of an active infection\n8. Pregnancy\n9. Presence of cognitive impairment, hearing loss, or communication difficulties that would prevent understanding of questionnaires and protocols","FEMALE","65 Years",{"count":59,"type":20},82,"Fibromyalgia is characterized by altered pain processing, including impaired descending pain inhibition and central sensitization. While both mechanisms have been independently associated with disease severity, their interrelationship remains unclear. This cross-sectional study aims to investigate whether central sensitization symptoms mediate the relationship between conditioned pain modulation and fibromyalgia impact.",[62,63,30,64,65],"Fibromyalgia (FM)","Quantitative Sensory Testing","PRESSURE PAIN THRESHOLD","Pain Perception",[67,68,69],"Fibromyalgia","Pain sensitization","Conditioned pain modulation","2026-06-05",{"date":72,"type":41},"2026-06-11",{"date":74,"type":20},"2026-06-01",{"date":76,"type":20},"2026-09-01",{"name":78,"class":48},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":49},"100597333","neuropathic-characteristics-of-subacromial-pain-syndrome-100597333","NCT07057128","Neuropathic Characteristics of Subacromial Pain Syndrome","Descriptors of Neuropathic Pain and Its Association With Central Sensitization in Subacromial Pain Syndrome","Inclusion Criteria:\n\n1. Clinical diagnosis of subacromial pain syndrome (SAPS)\n2. Age ≥ 19 years\n3. Shoulder pain lasting for at least 3 months\n4. Shoulder pain intensity rated as 3 or higher on the Visual Analog Scale (VAS) in the past week\n5. Positive findings on the following clinical tests:\n\nHawkins-Kennedy test Painful arc test Infraspinatus muscle strength test\n\nExclusion Criteria:\n\n1. History of inflammatory disease involving the shoulder joint\n2. History of neurological disorders\n3. History of prior shoulder surgery\n4. Positive drop arm test\n5. Loss of passive range of motion in the shoulder joint\n6. Presence of muscle strength loss\n7. Structurally confirmed shoulder pathology based on imaging studies\n8. Full-thickness tear of the rotator cuff muscles\n9. Presence of neurodeficit in the upper extremity\n10. Diagnosis of cancer or active infection\n11. Use of medications for neuropathic pain within the past 3 months for any reason","ALL","19 Years",{"count":59,"type":20},"This single-center observational study aims to investigate neuropathic pain descriptors and their relationship with central sensitization in patients diagnosed with subacromial pain syndrome (SAPS) who have had shoulder pain for at least 3 months. A total of 82 participants aged 19 years or older will be recruited from the Physical Medicine and Rehabilitation outpatient clinic of Izmir City Hospital. After obtaining informed consent, participants will complete validated questionnaires assessing pain severity (VAS), neuropathic pain characteristics (painDETECT), central sensitization (Central Sensitization Inventory), and shoulder function (SPADI). Range of motion will be measured using a goniometer. No imaging or invasive procedures will be performed. Using the central sensitization scale and pain detect, the presence or absence of the 7 pain descriptors will be investigated in patients with subacromial pain syndrome with or without central sensitization and neuropathic pain pattern and it will be investigated whether the contribution of hyperalgesia, one of these pain descriptors, to neuropathic pain and central sensitization in patients with subacromial pain syndrome is greater than the contribution of other pain descriptors.The results of this study are expected to provide insight into pain mechanisms and guide clinical management in patients with SAPS.",[91,30,92],"Neuropathic Pain","Subacromial Pain Syndrome","RECRUITING","2026-04-12",{"date":96,"type":41},"2026-04-14",{"date":98,"type":41},"2025-09-15",{"date":100,"type":20},"2026-06",{"name":102,"class":103},"Izmir City Hospital","OTHER_GOV",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":49},"100628934","the-impact-of-metabolic-status-on-pain-and-central-sensitization-in-women-with-lipedema-a-cross-sectional-observational-study-100628934","NCT07468097","The Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational Study","THE IMPACT OF METABOLIC STATUS ON PAIN AND CENTRAL SENSITIZATION IN WOMEN WITH LIPEDEMA: A CROSS-SECTIONAL OBSERVATIONAL STUDY","Inclusion Criteria:\n\n* Being female and aged 18 years or older\n* Having chronic pain persisting for at least 3 months\n* Having sufficient cognitive ability to understand and respond to the assessment scales used in the study\n* Voluntarily agreeing to participate in the study and providing written informed consent\n\nExclusion Criteria:\n\n* Presence of a history of malignancy, active infection, inflammatory rheumatic disease, or severe systemic disease\n* History of known neurological disorders (e.g., stroke, multiple sclerosis, epilepsy)\n* Diagnosis of severe psychiatric disorders (e.g., psychotic disorders, bipolar disorder)\n* Pregnancy or breastfeeding\n* Presence of cognitive impairment or communication difficulties that could affect the study results\n* Diagnosed diabetes mellitus\n* Active thyroid disease (uncontrolled hypothyroidism or hyperthyroidism)\n* Cushing's syndrome or other significant endocrine disorders\n* Use of antidiabetic medications\n* Use of lipid-lowering therapy (e.g., statins, fibrates)\n* Systemic glucocorticoid use within the past 3 months\n* Use of medications that may significantly affect central pain mechanisms (e.g., high-dose opioids, antipsychotic drugs)\n* History of major surgery or invasive treatment for pain within the past 3 months",{"count":112,"type":20},59,"The aim of this study is to evaluate the effect of metabolic markers (HOMA-IR, triglyceride\u002FHDL ratio, HbA1c, waist and hip circumference measurements, BMI, etc.) on pain and central sensitization in patients diagnosed with lipedema. The primary objective is to investigate the association between metabolic markers and central sensitization. The secondary objective is to assess the relationship between metabolic markers and pain intensity, pain phenotype, and functional status.",[30,115,116,117],"Lipedema","Pain","HOMA-IR",[119,117,116,120,121,115],"Triglyceride","Fasting Blood Glucose","Fasting Insulin","2026-03-09",{"date":124,"type":41},"2026-03-12",{"date":122,"type":41},{"date":127,"type":20},"2027-03-01",{"name":129,"class":48},"Marmara University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":86,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":49},"100567415","pain-perception-and-the-autonomic-nervous-system-100567415","NCT06667895","Pain Perception and the Autonomic Nervous System","Influences of the Autonomic Nervous System on Experimental Pain Sensitization","Inclusion Criteria:\n\n1. Over 18 and below 40 years of age\n2. Good general health\n3. Able to give informed consent\n\nExclusion Criteria:\n\n1. Any major medical or psychiatric condition (e.g. heart disease, diabetes, autoimmune disorders, infectious diseases, major depressive disorder), any chronic pain condition, any respiratory problems, any acute pain at time of study\n2. Inability to follow study instructions, e.g. due to language problems\n3. Pregnancy (female participants will be asked if pregnancy could be possible)\n4. Increased alcohol (\\>2 (for women)\u002F4 (for men) standard glasses per day or \\>5 (for women)\u002F4 (for men) glasses at least once a month within a few hours) or caffeine consumption (≥ 400mg per day)\n5. Consumption of alcohol, drugs, analgesics within the last 24 h\n6. Consumption of more than 100 mg of caffeine within the last 8 h\n7. Scar tissue or generally reduced sensitivity in the designated testing site areas\n8. Shoe size \\< 38 (if experiment is conducted at the feet)\n9. History of cardiovascular disease or carotid artery disease\n10. Medication or Substances inferring with the autonomic nervous system or with pain sensitivity (e.g. Benzodiazepines, Nicotine)",true,"40 Years",{"count":140,"type":20},146,"INTERVENTIONAL",[143],"NA","In this study, we want to investigate how pain processing and sensation are related to a certain part of the nervous system, the so-called autonomic nervous system.\n\nFor this purpose, we apply heat and pressure stimuli to the skin and test pain processing by means of ratings scales and sensory tests. Breathing, heart rate and sweat response are also measured. To assess the spinal cord level, we measure muscle response (measured by electromyography, EMG) to electrical stimulation. Additionally, sensory nerves will be stimulated at the ear and participants will also be given various questionnaires to complete.",[146,65,147,30,148],"Autonomic Nervous System Modulation","Pain Sensitivity","Vagus Nerve Stimulations","2024-10-30",{"date":151,"type":41},"2024-10-31",{"date":153,"type":20},"2024-11-04",{"date":155,"type":20},"2026-08",{"name":157,"class":48},"Schweinhardt Petra"]